Mild COVID-19 despite inadequate antibody response after repeated vaccinations in rheumatic disease patients with rituximab-induced B cell depletion: a case series

RMD Open. 2022 Dec;8(2):e002567. doi: 10.1136/rmdopen-2022-002567.

Authors

Alexander Ten Hagen^#¹, Elisa Habermann^#¹, Sandra Hermann¹, Gerd R Burmester¹, Robert Biesen¹, Fredrik N Albach²

Affiliations

¹ Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität, Berlin, Germany.
² Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität, Berlin, Germany fredrik.albach@charite.de.

^# Contributed equally.

No abstract available

Keywords: Autoimmune Diseases; B-Lymphocytes; COVID-19; Rituximab; Vaccination.

Publication types

Letter

MeSH terms

Antibody Formation
COVID-19* / prevention & control
Humans
Rheumatic Diseases* / drug therapy
Rituximab / adverse effects
Vaccination / adverse effects

Substances

Rituximab